Found: 9
Select item for more details and to access through your institution.
Clinical and pharmacokinetic study of TNP-470, an angiogenesis inhibitor, in combination with paclitaxel and carboplatin in patients with solid tumors.
- Published in:
- 2004
- By:
- Publication type:
- journal article
A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Phase 1b/2 Randomized Study of MEDI-575 in Combination With Carboplatin Plus Paclitaxel Versus Carboplatin Plus Paclitaxel Alone in Adult Patients With Previously Untreated Advanced Non-Small-Cell Lung Cancer.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Long-Term Safety and Tolerability of Sorafenib in Patients with Advanced Non-Small-Cell Lung Cancer: A Case-Based Review.
- Published in:
- Clinical Lung Cancer, 2011, v. 12, n. 4, p. 212, doi. 10.1016/j.cllc.2011.03.021
- By:
- Publication type:
- Article
First-In-Human Phase I Study Of A Dual mTOR Kinase And DNA-PK Inhibitor (CC-115) In Advanced Malignancy.
- Published in:
- Cancer Management & Research, 2019, v. 11, p. 10463, doi. 10.2147/CMAR.S208720
- By:
- Publication type:
- Article
A Phase 1b/2 Study of Alpelisib in Combination with Cetuximab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
- Published in:
- Targeted Oncology, 2023, v. 18, n. 6, p. 853, doi. 10.1007/s11523-023-00997-z
- By:
- Publication type:
- Article
Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Nivolumab treatment beyond RECIST-defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial.
- Published in:
- 2019
- By:
- Publication type:
- journal article
CheckMate 141: 1‐Year Update and Subgroup Analysis of Nivolumab as First‐Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer.
- Published in:
- Oncologist, 2018, v. 23, n. 9, p. 1079, doi. 10.1634/theoncologist.2017-0674
- By:
- Publication type:
- Article